» Articles » PMID: 32224979

External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase

Abstract

Ionising radiation causes cell death through the induction of DNA damage, particularly double-stranded DNA (dsDNA) breaks. Evidence suggests that adenoviruses inhibit proteins involved in the DNA damage response (DDR) to prevent recognition of double-stranded viral DNA genomes as cellular dsDNA breaks. We hypothesise that combining adenovirus treatment with radiotherapy has the potential for enhancing tumour-specific cytotoxicity through inhibition of the DDR and augmentation of virus production. We show that EnAd, an Ad3/Ad11p chimeric oncolytic adenovirus currently being trialled in colorectal and other cancers, targets the DDR pathway at a number of junctures. Infection is associated with a decrease in irradiation-induced 53BP1 and Rad51 foci formation, and in total DNA ligase IV levels. We also demonstrate a radiation-associated increase in EnAd production in vitro and in a pilot in vivo experiment. Given the current limitations of in vitro techniques in assessing for synergy between these treatments, we adapted the plaque assay to allow monitoring of viral plaque size and growth and utilised the xCELLigence cell adhesion assay to measure cytotoxicity. Our study provides further evidence on the interaction between adenovirus and radiation in vitro and in vivo and suggests these have at least an additive, and possibly a synergistic, impact on cytotoxicity.

Citing Articles

Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments.

Yan Z, Zhang Z, Chen Y, Xu J, Wang J, Wang Z Cancer Cell Int. 2024; 24(1):242.

PMID: 38992667 PMC: 11238399. DOI: 10.1186/s12935-024-03424-z.


The Future of Interventions for Stage IV Colorectal Cancers.

Lloy S, Lin M, Franko J, Raman S Clin Colon Rectal Surg. 2024; 37(2):114-121.

PMID: 38327731 PMC: 10843879. DOI: 10.1055/s-0043-1761624.


Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review.

Kumar A, Gautam V, Sandhu A, Rawat K, Sharma A, Saha L World J Gastrointest Surg. 2023; 15(4):495-519.

PMID: 37206081 PMC: 10190721. DOI: 10.4240/wjgs.v15.i4.495.


Current landscape and perspective of oncolytic viruses and their combination therapies.

Su Y, Su C, Qin L Transl Oncol. 2022; 25:101530.

PMID: 36095879 PMC: 9472052. DOI: 10.1016/j.tranon.2022.101530.


Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors.

Su Y, Li J, Ji W, Wang G, Fang L, Zhang Q J Immunother Cancer. 2022; 10(5).

PMID: 35609942 PMC: 9131115. DOI: 10.1136/jitc-2022-004691.


References
1.
Wang Y, Deng W, Li N, Neri S, Sharma A, Jiang W . Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Front Pharmacol. 2018; 9:185. PMC: 5844965. DOI: 10.3389/fphar.2018.00185. View

2.
Lee J, Cheong H, Kang M, Kim S, Kang Y . Ser1778 of 53BP1 Plays a Role in DNA Double-strand Break Repairs. Korean J Physiol Pharmacol. 2009; 13(5):343-8. PMC: 2776893. DOI: 10.4196/kjpp.2009.13.5.343. View

3.
Cuconati A, Mukherjee C, Perez D, White E . DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev. 2003; 17(23):2922-32. PMC: 289151. DOI: 10.1101/gad.1156903. View

4.
Chia S, Lei J, Ferguson D, Dyer A, Fisher K, Seymour L . Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer. Virology. 2017; 505:162-171. DOI: 10.1016/j.virol.2017.02.011. View

5.
Yang X, Xu X, Zhang S, Wu Y, Xing C, Ru G . Role of miR-100 in the radioresistance of colorectal cancer cells. Am J Cancer Res. 2015; 5(2):545-59. PMC: 4396051. View